Regulatory compliance - April 30, 2015
Drs. Resign Amid AZ Payment Probe
Two psychiatrists with Terrell State Hospital (TSH) in Texas, U.S., resigned after allegedly receiving hundreds of thousands of dollars from AstraZeneca, according to the Texas Department of State Health Services. Allegedly the two physicians violated several department rules related to their relationship with AstraZeneca and efforts to have the antipsychotic medication Seroquel XR placed on […]
Collaboration - April 29, 2015
AZ, Celgene Tackle Blood Cancer
AstraZeneca has entered into a $450 million agreement with Celgene that will permit the U.S.-based drug firm to develop MEDI4736, AstraZeneca’s immunotherapy treatment for blood cancer. The agreement sent Celgene’s stock surging. AstraZeneca officials say the deal is a way to get the drug to market faster, according to Reuters. Blood cancer treatments eventually will […]
Uncategorized - April 29, 2015
NordForsk Funds Two Projects
Norway’s NordForsk Board has awarded a total of NOK 11 million to two Nordic-Baltic research projects on user-driven innovation in health and welfare. The two were selected from among 34 submissions. The overall goal of the Nordic Program on Health and Welfare is to improve health in the Nordic countries by conducting high-quality research to find […]
Clinical Trials - April 28, 2015
Trial Starts for PPMS Drug
Teva Pharmaceutical Industries Ltd. and Active Biotech enrolled the first patient in their study A RandomizedPlacebo-controlled Trial Evaluating Laquinimod in primary progressive multiple sclerosis (PPMS), Gauging Gradations In MRI and Clinical Outcomes (ARPEGGIO), a Phase II study to evaluate laquinimod. This is an investigational, oral, immune modulator, for PPMS, which currently has no approved treatments. PPMS affects approximately 15 percent of all MS patients […]
Profiles in Business - April 28, 2015
Remaining at the forefront
Jan-Olof Jacke, AstraZeneca AB’s new CEO, on maintaining the company’s position in Sweden. Keeping AstraZeneca AB in the forefront – as a research and marketing leader, a key component of Sweden’s domestic economy and export business and as a contributor to AstraZeneca’s overall growth – are priorities that AstraZeneca AB’s CEO Jan-Olof Jacke brings to […]
Acquisition - April 28, 2015
Unnamed Bidders Approach Sobi
Swedish Orphan Biovitrum (Sobi) has been approached by bidders, but the company is not revealing the names of the interested parties. The company recently issued a statement saying “that it has received a preliminary and conditional non-binding proposal in relation to a possible offer for all shares issued by the company.” Word of the proposed takeover […]
